W. L. Gore & Associates, Inc. (Gore) today announced that it has extended its distribution agreement in the US and Canada with ConMed Endoscopic Technologies for the distribution and marketing of its GORE(R) VIABIL(R) Biliary Endoprosthesis. "We are very excited to announce this exclusive contract extension with ConMed," said Gore Medical Products Business Leader, Ron Anderson. "This will assure that interventional gastroenterologists have increasing access to the GORE VIABIL Biliary Endoprosthesis, which has the proven clinical benefits of low migration and long-term patency." "Over the past several years, GORE VIABIL Biliary Endoprosthesis, with its cadre of technological benefits, has assisted the GI community in delivering enhanced patient outcomes," said Mark Donovan, Vice President of ConMed Endoscopic Technologies.
BiO2 Medical has announced that it has received CE mark approval for the Angel Catheter, a nitinol inferior vena cava (IVC) filter, permanently attached to a central venous catheter (CVC) for the use of preventing pulmonary embolism in critically ill patients with venous thromboembolism for whom anticoagulation therapy is temporarily contraindicated.
PARIS -- More dramatic blood pressure reductions may be on the horizon for patients with resistant hypertension given the phalanx of renal denervation systems under development.
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced that preliminary data demonstrated the company’s EnligHTN™ renal denervation system was safe and effective for the treatment of resistant hypertension. The study demonstrated that on average patients with resistant hypertension experience a systolic blood pressure reduction of 28 points after 30 days.
St. Jude Medical, Inc. (NYSE:STJ ), a global medical device company, today announced CE Mark Approval and launch of its EnligHTN™ renal denervation system during EuroPCR. Renal denervation is a specialized ablation procedure that has been clinically proven to reduce blood pressure in patients with hypertension, or high blood pressure, that is resistant to medical therapy. Clinical data from the EnligHTN I trial about the safety and efficacy of the company’s renal denervation technology will be presented on Wednesday.
CryoLife, Inc. (CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that it has signed a definitive agreement to acquire Hemosphere, Inc., a privately-held medical device company that has developed and markets the HeRO (Hemodialysis Reliable Outflow) Graft. The HeRO Graft is a proprietary graft-based solution for end-stage renal disease (ESRD) hemodialysis patients with limited access options and central venous obstruction.
At ECIO 2012, David J Breen, Department of Radiology, University of Southampton School of Medicine, UK, shared with delegates 10 top tips for optimising outcomes in microwave ablation of the liver. The talk was part of a satellite symposium supported by Microsulis Medical.
Boston Scientific Corporation (NYSE: BSX) announces CE Mark and European market launch of the Innova Self-Expanding Bare-Metal Stent System, which is designed to treat peripheral vascular lesions in arteries above the knee, specifically the superficial femoral artery (SFA) and proximal popliteal artery (PPA). The company plans to launch the product immediately in Europe and other CE Mark countries.
ReCor Medical, an emerging medical device company, announced today that it has completed enrollment in the REDUCE 15-patient pilot clinical study of its PARADISE (Percutaneous Renal Denervation System) ultrasound platform for achieving renal denervation. PARADISE, which is CE-marked, is designed to treat patients with ‘resistant’ hypertension (“HTN”), a major risk factor for cardiovascular disease.
ActiViews, Inc, a company pioneering the development of simple, accurate, and cost-effective surgical navigation solutions, announced today the first successful procedure in the United States with CT-Guide™ navigation. The procedure was performed by Sebastian Flacke, M.D., Ph.D., Director of Interventional Radiology and Vice Chair for Research at the Lahey Clinic in Burlington, Massachusetts. Dr. Flacke utilized CT-Guide™ navigation for a successful lung biopsy of a small, deep abnormality in the patient’s middle right lobe.
Covidien (NYSE: COV ), a leading global provider of healthcare products, will unveil its new OneShot™ renal denervation system at the EuroPCR congress in Paris, France, on May 16, 2012. Adding to the Company’s broad and growing vascular therapies portfolio, the OneShot system is designed to treat patients with hypertension who are not responsive to traditional medical therapy.
El Hospital Universitario de La Ribera, líder en la aplicación de la radiofrecuencia para el tratamiento de tumores pulmonares. El centro hospitalario ha celebrado una sesión de trabajo en la que han participado destacados profesionales de varias comunidades autónomas.
The US Food and Drug Administration (FDA) has given 510(k) clearance to ActiViews to market its CT-Guide Needle Guidance System for liver interventions. CT-Guide navigation is designed to assist physicians during CT-guided interventional diagnostic and therapeutic procedures such as percutaneous biopsies, ablations, and marker placements in the lung and liver. The system features a single-use miniature video camera that is easily affixed onto standard interventional instruments, a patented sterile registration sticker, and proprietary 3D software that is viewed on a HD flat panel monitor mounted on a mobile workstation. CT-Guide navigation allows physicians to determine the location of the navigated instrument in relation to the 3D space of the CT images and the desired target, continuously displaying the location of the instrument and its planned path on the CT image of the patient’s anatomy.
C. R. Bard, Inc. (NYSE: BCR) today announced that Christopher S. Holland has been named Senior Vice President and Chief Financial Officer, effective May 21, 2012. In this role, Mr. Holland will report directly to Timothy M. Ring, Chairman and Chief Executive Officer. BUSINESS WIRE.
Six Month Pooled Outcomes From Randomized and Crossover Patients Following Renal Denervation Presented at the 22nd Annual Scientific Meeting of the European Society of Hypertension Confirm Previous Symplicity Clinical Trial Findings
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos